There are limited data suggesting that initiation of epoetin alfa at extended dosing interals of eery 2, 3, or 4 wk may be efficacious for treating anemia in patients who hae chronic kidney disease and are not on dialysis (CKD-NOD).

• 有限的资料显示：扩大初始的给药间隔时间到2，3，或者4周，对应用重组人红细胞生成素治疗慢性肾脏病未透析患者(CKD-NOD)的贫血是有效的。